In a follow up story to Roche's announced operational excellence cuts this morning, Xconomy reports that Genentech manufacturing staff will see cuts in South San Francisco (350-450), Vacaville (100) and Oceanside (90), but nobody from R&D or early drug development is expected to go.
The handwriting has essentially been on the wall for a lot of the manufacturing operations in South San Francisco. As far back as 2006, Genentech said it was planning to shift the manufacturing group on campus away from commercial output, and gear it more toward producing batches for use in clinical trials, said Genentech spokeswoman Robin Snyder. The cuts will commence now and be completed by 2012.
Posted by Bruce Lehr November 17th 2010.